Siva Receives US China Innovation Alliance Award and Prepares for Trip to China

HOUSTON, TEXAS, May 18, 2018 – Siva Therapeutics (“Siva”) is pleased to announce that it has received a Judges Choice Award as a finalist at the 2018 US China Innovation Alliance (UCIA) competition in Houston, Texas.  These awards were given to selected finalists in the UCIA InnoSTARS competition, and they include travel to China to meet with prospective investors and partners in June, 2018.

The UCIA, which has a growing presence in Houston, started the InnoSTARS competition in 2017 to identify technologies of interest for investment by, and partnership with, Chinese organizations.  Their selection process involves a progressive series of pitch competitions, culminating in selection of finalists for the awards given in Houston.  Siva was a “Judges Choice” winner and fast-tracked for the June delegation to China.

“We’re honored to receive this award from the UCIA.” said Len Pagliaro, PhD, CEO of Siva.  “The potential for productive collaboration with, and investment from, groups in China is growing rapidly, particularly with nanomanufacturing and clinical trial capabilities expanding quickly.  We value this award and look forward to our visit next month.”

About Siva Therapeutics Inc                              

Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancers. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be extremely safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Siva’s initial clinical targets include melanoma and head & neck cancer.

Contact us at info@sivatherapeutics.com or visit: www.sivatherapeutics.com

About the UCIA                                            

The US China Innovation Alliance (UCIA) is a non-profit 501(c)(3) tax-exempt organization that promotes innovation through the exchange of ideas and collaboration between China and the US. We organize the annual US China Innovation and Investment Summit (UCIS) in Houston, which provides a unique opportunity for innovative technology startups to connect with investors, strategic partners, leading incubators/accelerators, and professional services firms from China. It is an excellent platform for technology companies to leverage significant resources from China to accelerate their growth and to expand their market potential. In 2017, we launched the InnoSTARS Competition, which allows growth-stage technology companies in five core industry areas to compete for the chance to win attendance to UCIS as well as an all-expenses paid roadshow to China, where they will have an opportunity to showcase their business and products to a wide audience of qualified potential investors and relevant partners. The UCIA also organizes roadshows to bring innovative US technology companies to China for B2B matchmaking and provides other services to help US-based companies connect with complimentary Chinese resources.

For more information visit:  https://uschinainnovation.org/.

View a .pdf of this press release here.

Siva Receives Patent for SivaLum™ Light Engine

AUSTIN, TEXAS, May 16, 2018 – Siva Therapeutics (“Siva”) is pleased to announce that it has received Notice of Allowance from the US Patent and Trademark Office on all 24 claims in its Patent Application number 14/567,077 entitled “Multifunctional Radiation Delivery Apparatus and Method.”

This patent covers many aspects of the design and use of the “smart” SivaLum™ light-emitting diode-based light engine for delivering safe, high intensity infrared light over a large area as a key element of Siva’s Targeted Hyperthermia™ photothermal cancer therapy. Together with SivaRods™ precision polymer-coated gold nanorods, the SivaLum is part of an optimized system for delivering Targeted Hyperthermia to solid tumors. The term “radiation” in the patent title refers broadly to electromagnetic radiation, including infrared light; Siva’s technology involves no ionizing radiation, which has harmful effects on humans.

“The light engine patent is an important milestone for Siva.” said Len Pagliaro, PhD, CEO of Siva. “It confirms our belief that Siva’s systems approach to implementing practical photothermal therapy has been the best path to follow. Other efforts that have used sub-optimal existing lasers for illumination have not met with the success of our custom-designed and optimized SivaLum light engine that has been paired with optimized SivaRods to form an integral system to deliver Targeted Hyperthermia. Together with our pilot-scale SivaRod manufacturing, the SivaLum places us a step closer to the clinic for first-in-human studies.”

About Siva Therapeutics Inc
Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancers. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be extremely safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Siva’s initial clinical targets include melanoma and head & neck cancer.
Contact us at info@sivatherapeutics.com or visit: www.sivatherapeutics.com

View a .pdf of this press release here.

Siva’s Targeted Hyperthermia™ Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research

AUSTIN, TEXAS, July 18, 2017 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md.

FNL’s Nanotechnology Characterization Laboratory (NCL) – a partnership with the U.S. Food and Drug Administration and the National Institute of Standards and Technology – is a world leader in the characterization of therapeutic nanoparticles, which helps pave the way for regulatory review of nanotechnologies intended for cancer therapies and diagnostics.

The NCL uses a three-tiered assay cascade to thoroughly characterize each nanomaterial strategy submitted to the lab for physical and chemical attributes, in vitro biological properties, and in vivo compatibility through preclinical toxicology, pharmacology, and efficacy studies. Through an application process, NCL offers preclinical characterization services to investigators nationwide who have developed promising nanotechnology-based cancer treatments. NCL’s assay cascade takes about a year to complete.
Continue reading “Siva’s Targeted Hyperthermia™ Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research”

Siva’s Targeted Hyperthermia™ Program Accepted by the Nanotechnology Characterization Laboratory

AUSTIN, TEXAS, August 29, 2016 – Siva Therapeutics (“Siva”) is pleased to announce that its Targeted Hyperthermia™ technology has been accepted has been accepted for characterization by the Nanotechnology Characterization Laboratory (NCL) in Frederick, Maryland. The NCL is a national resource which facilitates the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical NCL logoinfrastructure and characterization services, the NCL accelerates the transition of nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.

Continue reading “Siva’s Targeted Hyperthermia™ Program Accepted by the Nanotechnology Characterization Laboratory”

Siva Therapeutics Publishes in the Journal of Nanomaterials

BOULDER, COLORADO, August 7, 2014 – Siva Therapeutics has had a manuscript accepted for publication in the Journal of Nanomaterials.  The forthcoming paper, entitled “Photothermal therapy using gold nanorods and near-infrared light in a murine melanoma model increases survival and decreases tumor volume” by Mary Popp and colleagues, describes Siva’s approach to photothermal monotherapy for melanoma, using the aggressive B16F10 mouse melanoma model.  The study also describes the tissue and gel models used to develop and calibrate the photothermal therapy approach.

Continue reading “Siva Therapeutics Publishes in the Journal of Nanomaterials”

Siva Therapeutics Initiates Research Collaboration with SomaLogic Inc.

BOULDER, COLORADO, March 18, 2014 – Siva Therapeutics (“Siva”) has initiated a research collaboration with SomaLogic, Inc. (Boulder, CO). The initial focus of the collaboration is to determine the ability of SomaLogic’s SOMAmer® (Slow-off Rate Modified Aptamer) reagents to actively target gold nanorods to solid tumors. Continue reading “Siva Therapeutics Initiates Research Collaboration with SomaLogic Inc.”

Siva Therapeutics Initiates Research Collaboration with Plexxikon Inc.

PlexxikonBOULDER, COLORADO, January 23, 2014 – Siva Therapeutics Inc (‘Siva’) has initiated a research collaboration with Plexxikon Inc., of Berkeley, California. The focus of the collaboration is to evaluate the potential for synergistic effects between Zelboraf®, a cancer treatment approved for BRAF V600E mutation-positive metastatic melanoma discovered and co-developed by Plexxikon, and SivaRods™ photothermal therapy. Continue reading “Siva Therapeutics Initiates Research Collaboration with Plexxikon Inc.”

Siva Therapeutics Completes Efficacy Study in Melanoma Model and Files FDA Pre-Submission

BOULDER, COLORADO, July 10, 2013 – Siva Therapeutics Inc (‘Siva’) has generated very positive efficacy results in a challenging mouse melanoma model, using SivaRods™ photothermal therapy. In the study, significant decreases in tumor volume and increased survival, relative to control animals, were seen.  Continue reading “Siva Therapeutics Completes Efficacy Study in Melanoma Model and Files FDA Pre-Submission”